New early stage VC Apuri seeks to seed China’s academic discoveries

Today’s peer-reviewed journals are filled with Chinese academic labs opening new possibilities for biotech, generating as many papers as the U.S. produces. That bolus of innovation has created a need for company builders in China who can translate the discoveries into biotech companies that can compete on the world stage and attract Western buyers. 

With an interdisciplinary team of three whose experiences span the biotech C-suite, investment banking, venture capital and academia, early-stage Shanghai VC Apuri believes it is well positioned to build biotechs from the outflow of discoveries emerging from the labs of China’s research institutions. The firm is raising its debut fund...